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Abstract
The anticancer activity of titanium complexes has been known since the groundbreaking studies of Ko ¨pf and Ko ¨pf-Maier on
titanocen dichloride. Unfortunately, possibly due to their fast hydrolysis, derivatives of titanocen dichloride failed in clinical
studies. Recently, the new family of titanium salan complexes containing tetradentate ONNO ligands with anti-cancer
properties has been discovered. These salan complexes are much more stabile in aqueous media. In this study we describe
the biological activity of two titanium salan complexes in a mouse model of cervical cancer. High efficiency of this promising
complex family was demonstrated for the first time in vivo. From these data we conclude that titanium salan complexes
display very strong antitumor properties exhibiting only minor side effects. Our results may influence the chemotherapy
with metallo therapeutics in the future.
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Introduction
The discovery of the anticancer effects of cisplatin and its
clinical introduction in the 1970s represents an important step in
the history of the development of cancer drugs. Today, this metal
based complex and its next generation analogues, carboplatin and
oxaliplatin, play an important role in tumor therapy, but the
existing complexes are efficient in only a limited range of cancers
and can induce acquired resistance upon treatment [1]. They also
often cause severe side-effects like nausea, bone marrow
suppression and kidney toxicity [1,2]. Current research on metal
complexes is therefore directed to the investigation of other
platinum-based compounds as well as non-platinum metal-based
systems with little cross resistance to cisplatin and less side effects
[3–7]. Among these, titanium(IV)complexes showed encouraging
antitumor activity in various cell lines [8–10].
Till today, three classes of cytotoxic titanium complexes are
known. Most of the complexes investigated so far are derivatives
of either titanocene dichloride (Cp2TiCl2) [11] or diketonato-
complexes like budotitane [Ti(bzac)2(OEt)2; Hbzac = Phenylbu-
tane-1,3-dione] [12]. Representatives of these two classes of
complexes were tested in clinical trials, but unfortunately, no
objective clinical responses were observed [13,14]. The main
disadvantages of these titanium complexes are their fast
hydrolysis under physiological conditions: in an aqueous
environment, the loss of the labile groups occurs within seconds
[15,16].
With hydrolytic half lives in the range of hours, salan
complexes of titanium are much more stable [17]. Exploring
this new, third class of titanium complexes with antitumor
activity, we could demonstrate that their biological properties can
be fine-tuned by varying the substitution pattern of the
complexes. The most promising subgroup contains salan
complexes bearing halogen residues at the aromatic rings. The
IC50 values of these halo-salan complexes are comparable to
cisplatin and in contrast to their alkyl-substituted counterparts,
they almost exclusively induce apoptotic cell death [18].
Moreover, we could demonstrate that these complexes are
effective in a cisplatin-resistant cell line [17].
Up to now, few is known about the mechanism of action and
cellular uptake of the titanium salan complexes on the one and
selectivity and in vivo applicability on the other hand. Therefore,
we have selected cervical cancer for first preclinical studies.
Worldwide approximately 370,000 cases of cervical cancer are
being diagnosed each year and almost 200,000 deaths are
attributed to this disease [19]. In developed areas the treatment
bases mainly on surgery and chemotherapy but nevertheless even
when optimal treatment is available about 40% of all cervical
cancer patients die of this disease [20]. Therefore, the
development of effective and save new anticancer drugs is
necessary.
In the current study we analyzed the potency of two titanium
salan complexes to induce cell death in C3 cells in vitro and tumor
regression in C57BL/6 mice.
Results
As we reported previously, the halogen substituted complexes
are highly active against various human cancer cells and nearly
exclusively induce apoptotic cell death. Moreover, they display an
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life of more than 4 days in aqueous media is therefore a promising
substance (for an overview of their physicochemical and biological
properties see table 1) [17,18]. The aim of this study was to
characterize the activity of two promising titanium salan
complexes in more detail and to evaluate their potential clinical
value. For this purpose we investigated the biological activity using
a broad variety of cancer cell lines in vitro and, importantly, the
well established C3 mouse model in vivo.
Titanium salan complexes were synthesized in high
yields
Complexes 1 and 2 were accessible by refluxing the appropriate
phenol N,N’-dialkylethylenediamine, and formaldehyde in meth-
anol and metallating the resulting ligands with titanium tetra-
isopropoxide (Ti-(O
iPr)4) [18]. To remove trace impurities, the
complexes were recrystallized at least once from n-hexane or
toluene and purities were proven by combustion analysis (for
details see materials and methods). This elegant two step synthesis
allowed for the preparation of the complexes in high yields (more
than 10 g, respectively) and purity (Figure 1).
Complexes 1 and 2 are able to suppress cell proliferation
in the murine C3 model of cervical cancer but also in
various human cancer cells in vitro
To test efficacy of complexes 1 and 2 in C3 cells, both
compounds were tested using the well-established AlamarBlue
assay. This assay commonly used to determine cell proliferation is
known to be highly reproducible and more sensitive than the
MTT assay. The obtained dose-activity curves for complexes 1
and 2 in C3 cells are shown in Figure 2. With an IC50 value of
2.260.1 mM complex 1 was highly active in C3 cells. In fact, it
represents one of the most active titanium salan complexes found
so far. Complex 2 was slightly less toxic, the IC50 value was
8.661.3 mM (Figure 2). Both IC50 values are given as mean values
from at least three independent experiments each done in four
replicates. These IC50-values are comparable to those found for
these complexes in the human cancer cell lines HeLa S3 and Hep
G2.
To further show the broad applicability of these halogen
substituted titan salan complexes, complex 1, representing the
most active complex, was sent to the US National Cancer Institute
(NCI) for testing its activity in 57 human tumor cell lines (NCI60
anticancer drug screen). In 17 cell lines the complex was only
slightly active with an IC50 value of more than 100 mM. In
particular, it was not toxic to every of the leukemia cell lines tested
so far. In further 20 cell lines, the complex showed a mediocre
activity between 10 and 100 mM. In 19 tumor cell lines, the
complex was highly active with IC50 values below 10 mM. Especial
melanoma cells seem to be extremely sensitive to titanium salan
complexes. Together, we conclude that complex 1 suppresses
tumor cell proliferation in vitro in more than two thirds of all cell
lines investigated (Table 2, 3, and 4). The complete data are shown
in the supporting information (Figure S1).
.
Both titanium salan complexes are well tolerated in
animals up to single doses of 25 mg/kg
In a first experiment we investigated the tolerance of titanium
salan complexes 1 and 2 in direct comparison to conventional
cisplatin in animals. Thereby, we hypothesized that the complexes
are much more tolerated in direct comparison to cisplatin and
decided to compare a well established dose of cisplatin in the
murine model with different doses of the compounds. Mice (n=6/
group) received 2 mg/kg cisplatin [21] or once 50, 25, 12.5 or
5 mg/kg of the complexes 1 and 2, respectively. Noteworthy, after
30 days all mice of the cisplatin group and all animals of the 50
and 25 mg/kg groups (complex 1 and 2, respectively) displayed
clear signs of side effects like hair loss, apathy up to death (data not
shown). Interestingly, all animals of the other complex-treated
groups (25, 12, 5 mg/kg, respectively) survived and no fatal side
effects were observed by eye. From this outcome we decided to test
first a 30 mg/kg dose given at multiple applications (m.a.) (5 mg/
kg on days 0, 2, 4, 7, 9, 11, respectively [30 mg/kg m.a. group])
versus a 50 mg/kg dose also given at m.a. (30 mg/kg on day 0 and
20 mg/kg on day 9 [50 mg/kg m.a. group]) treatment regime in
the next set of experiments.
Table 1. Physicochemical and biological properties of
complexes 1 and 2.
properties of complexes 1, 2 complex 1 complex 2
IC50 value in Hela S3 1.660.1 mM5 . 3 60.2 mM
IC50 value in Hep G2 2.260.2 mM4 . 0 60.2 mM
hydrolytic half life 6 h 108 h
apoptotic/dead cells in Hela S3 90.164.4% 95.562.0036%
IC50 values were determined using an AlamarBlue Assay after 48 h of
incubation with different concentrations of the complexes. The hydrolytic half
life was determined using time resolved
1H-NMR. These hydrolysis experiments
were conducted in a mixture of 95% [D8]THF and 4.8% D2Oa t3 7 uC. As an
internal standard, 0.2% DMSO was added. Cell death was followed via double
staining with propidium iodide and fluorescein isothiocyanate-labeled annexin
V.
doi:10.1371/journal.pone.0017869.t001
Figure 1. Synthesis of the salan ligands and titanium salan complexes. The halo-salan ligands L
1 and L
2 were synthesised via a Mannich-
condensation of the respective phenol, formaldehyde and N,N’-ethylenediamine. The ligands were then metallated with Ti(O
iPr)4 in toluene to give
complexes 1 and 2.
doi:10.1371/journal.pone.0017869.g001
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transplantable mouse tumor model for cervical cancer
We were interested to investigate the therapeutic in vitro effects
of the two titanium salan complexes and took advantage of the
well established C3 tumor model of cervical cancer [22]. After
animals (n=10/group) had developed palpable tumors (2–4 mm
2
in average) treatment was started (day 0).
Two groups received 30 mg/kg at m.a. (days 0, 2, 4, 7, 9, 11)
and control animals received DMSO/PBS/Tween in the same
time scale. We observed a significantly reduced tumor growth in
the 30 mg/kg m.a. group that received complex 1 (122623 mm
2
vs 240632 mm
2 in the control group, p-value: 0.008) at day 31
whereas the effect was dramatically enhanced within the 30 mg/
kg m.a. dose group treated with complex 2 (34612 mm
2, p-value
to the control group: 0.0001, p-value to the 30 mg/kg m.a.
complex 1 group: 0.03) (table 5).
In order to determine the effects of a 50 mg/kg dose regime
combined with a lower application frequency on the tumor
growth, two further groups were treated with 30 mg/kg (day 0)
followed by an injection of 20 mg/kg (day 9) with the respective
titanium salan complex (50 mg/kg m.a.). Compared to the
control group (DMSO/PBS/Tween) both compounds mediate
significant tumor regression (p-values for both complexes:
0.0001).
Interestingly, no total tumor regressors were found within the
30 mg/kg m.a. groups. In contrast, 2 total tumor regressors (no
tumor palpable) were documented in the 50 mg/kg complex 1
Figure 2. Viability of C3 cells after incubation for 48 h with complexes 1 and 2. Dose-response curves were obtained using an AlamarBlue
assay. Measuring the fluorescence and comparison to a negative control gave the relative amount of cells surviving the treatment. The shown dose-
effect curves result from three independent test series done in four replicates.
doi:10.1371/journal.pone.0017869.g002
Table 2. IC50-values of titanium salan complex 1 in Breast-,
Colon-, and CNS human cancer cell lines.
Breast
Cancer IC50
Colon
Cancer IC50
CNS
Cancer IC50
MCF7 .100 mM COLO 46.3 mM SF-268 7.4 mM
MDA-MB-231/
ATCC
.100 mM HCT-116 29.2 mM SF-295 6.0 mM
HS 578T .100 mM HCT-15 .100 mM SF-539 .100 mM
BT-549 32.5 mM HT29 8.7 mM SNB-19 .100 mM
T-47D 60.1 mM KM12 17.6 mM SNB-75 8.8 mM
MDA-MB-468 9.9 mMS W - 6 2 0 9 . 4 mM U251 4.6 mM
Cells were cultivated in 96 well plates and incubated with a dilution series
containing five different concentrations of complex 1. The cells were fixed,
stained with sulforhodamine B and compared to a control. From the dose-
response curves (see supplements, Figure S1), the IC50-values were calculated.
The full test protocol is available under http://dtp.nci.nih.gov/branches/btb/
ivclsp.html.
doi:10.1371/journal.pone.0017869.t002
Table 3. IC50-values of titanium salan complex 1 in
Melanoma-, Lung-, and Renal human cancer cell lines.
Melanoma IC50
Lung
Cancer IC50
Renal
Cancer IC50
LOX IMVI 6.5 mM A549/ATCC 39.8 mM 786-0 14.8 mM
MALME-3M 4.3 mM EKVX 59.5 mM A498 6.8 mM
M14 6.7 mM HOP-92 3.6 mM ACHN .100 mM
MDA-MB-435 5.7 mM NCI-H226 .100 mM CAKI-1 44.9 mM
SK-MEL-2 37.6 mM NCI-H23 6.6 mM RXF 4.4 mM
SK-MEL-28 5.4 mM NCI-H322M 20.3 mM SN12C 43.3 mM
SK-MEL-5 4.3 mM NCI-H460 30.9 mM TK-10 .100 mM
UACC-257 12.6 mM NCI-H522 5.3 mM UO-31 24.2 mM
UACC-62 .100 mM
Conditions of treatment, see table 2.
doi:10.1371/journal.pone.0017869.t003
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2) and 3 total regressors were
observed within the complex 2 treated animals (tumor size:
1166m m
2). In direct comparison of the 30 mg/kg vs the 50 mg/
kg groups, both complexes are more effective at higher doses (p-
values: 0.0003 for complex 1 and 0.1 for complex 2) (table 5).
But in contrast to the 30 mg/kg m.a. application regime side
effects like alopecia and apathy were observed in all animals
treated with 50 mg/kg, especially in the complex 1 group (data
not shown). From this set of experiments we conclude that
titanium salan complex 2 is well tolerated and highly active in vitro
at 30 mg/kg dose given at m.a.
Next, we wanted to know if the observed therapeutic tumor
effect of the well tolerated complex 2 (30 mg/kg at m.a.) could be
enhanced without strengthen any side effects. Therefore, tumor-
bearing animals (n=10/group) were treated either with 50 mg/kg
at m.a. (day 0: 30 mg/kg, day 7: 20 mg/kg) or with a single dose
of 30 mg/kg (day 0). Again, control animals received DMSO/
PBS/Tween (days 0, 7) and reached at day 29 a tumor size of
268624 mm
2. A comparable therapeutic effect as in the first set of
in vivo experiments was observed in the 50 mg/kg m.a. group
(tumor size: 1263m m
2, p-value to the control: ,0.0001) (see
table 6). As mentioned above, side effects like alopecia and apathy
were observed. In contrast, animals of the 30 mg/kg s.a. group
developed significant larger tumors (6469m m
2, p-value to the
50 mg/kg m.a. group: ,0.0001) and no alopecia but mild apathy
were observed. A comparison of the 30 mg/kg m.a. (table 5) with
the 30 mg/kg s.a. (table 6) reveals higher efficacy if the drug is
applied distributed over 11 days (p-value: 0.06). The single
application (s.a.) of 30 mg/kg of complex 2 is therefore less
effective than the application of the same complex amount at
multiple days.
Together, these experiments imply that the titanium salan
complex 2 combines strong antitumor effects in vitro and in vivo and
is highly tolerated when given at low doses distributed over
multiple injections.
Discussion
In this study we were able to confirm the cytotoxicity of two
titanium salan complexes in various cell lines and showed for the
first time the activity of this class of complexes in vivo. We were able
to demonstrate that one out of two complexes investigated in this
study combines high antitumoral effects with a low adverse
reaction profile.
Titanium salan complexes represent a promising group of
chemotherapeutic agents, belonging to the class of metallo drugs.
Cisplatin as the first metallo therapeutic agent used in chemo-
therapy was first synthesized in the nineteenth century but clinical
application did not commence until the 1970s. After this major
landmark in the history of successful drugs for the treatment of
cancer, carboplatin as a safer second generation analogue was
introduced approximately ten years later. Next, the development
of improved analogues slowed for many years but recently the
interest in well tolerated and effective metallo therapeutic
compounds has increased. Aiming for more effective and less
toxic substances, titanium complexes attracted attention. Herein,
we could show that such titanium complexes are effective in a
variety of cancer cells. In tests on 57 human cancer cell lines,
titanium salan complexes showed mediocre activity in 20 cell lines
and high activity with IC50 values below 10 mM in 19 tumor cell
lines. These results encouraged us to further investigate the
applicability of these complexes as anti cancer drugs. As we
decided to use the well established mouse C3 model for cervical
cancer, we tested the activity of our complexes against C3 cells in
vitro and, more importantly, in vivo.
Indeed, cervical cancer is one potential field of application for
the titanium salan complexes due to the fact that survival in
women with recurrent or metastatic cervical cancer remains poor
and therefore, more effective and less toxic regimes are needed.
The superiority of the complex 2 in contrast to the complex 1
counterpart is especially interesting because 1 showed a nearly
four fold higher activity against C3 cells in vitro. This observation
could be explained by the much higher stability of complex 2 in
aqueous media. With a half life of 106 h, this complex is nearly 20
times as stabile as its fluoro counterpart complex 1. It seems that a
hydrolytic detoxification of complex 1 leads to a lower effective
dose of the active substance on the one hand. On the other hand,
Table 4. IC50-values of titanium salan complex 1 in Ovarian-,
Leukemia-, and Prostate human cancer cell lines.
Ovarian
Cancer IC50 Leukemia IC50
Prostate
Cancer IC50
IGROV1 6.2 mM CCRF-CEM .100 mM PC-3 28.6 mM
OVCAR-3 4.6 mM HL-60(TB) .100 mM DU-145 21.0 mM
OVCAR-4 78.7 mM K-562 .100 mM
OVCAR-5 57.2 mM MOLT-4 .100 mM
OVCAR-8 .100 mMS R .100 mM
NCI/ADR-RES .100 mM
SK-OV-3 59.1 mM
Conditions of treatment, see table 2.
doi:10.1371/journal.pone.0017869.t004
Table 5. Growth of established C3 tumors in C57BL/6 mice after treatment with titanium salan complexes 1, 2.
average tumor size at
day 0 (mm
2) ± S.E.M
average tumor size at
day 31 (mm
2) ± S.E.M
number of total regressors
at day 31
complex 1* (30 mg/kg m.a.) 3621 2 2 623 0
complex 2* (30 mg/kg m.a.) 3613 4 612 0
complex 1
# (50 mg/kg m.a.) 2611 2 682
complex 2
# (50 mg/kg m.a.) 4621 1 663
DMSO/PBS/0.5% Tween 80 2612 4 0 632 0
Mice received tumor cells s.c. into the flank and were treated either with 30 mg/kg at multiple applications (m.a.) (days 0, 2, 4, 7, 9, 11 with 5 mg/kg, respectively) (*) or
with 50 mg/kg at m.a. (day 0: 30 mg/kg and day 9: 20 mg/kg) (
#). Data gives the mean 6 SEM at days 0 and 31 and the number of completely tumor free animals.
Because of the size of tumors in the control group the experiment was terminated at day 31. One representative of two experiments is shown.
doi:10.1371/journal.pone.0017869.t005
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the more pronounced side effects observed with complex 1.I n
fact, the titanium salan complex 2 mediates strong suppression of
the tumor growth even when administered at relative low doses
and combines this feature at this dosage with outstanding
tolerance. Interestingly, the repeated low dose application regime
(six times 5 mg/kg, respectively) was most effective which could be
explained by prolonged in vivo drug availability.
Together, the compound 2 holds promise for a more effective
anticancer treatment approach in humans. This is especially true
as we could show, that this complex is highly active against
cisplatin resistant human bladder cancer cell line MGH-U1 and a
cross resistance to cisplatin is not observed [17]. These results will
also influence the search of new titanium complexes. A further
improvement of the stability in aqueous media may for example be
achieved by varying the labile ligands. In the case of titanocene
derivatives, this strategy has already been successful [23].
Because we are experienced in the development of therapeutic
vaccines against cervical cancer [24–27] we will next combine
immunotherapy time-shifted to treatment intervals with the
titanium salan complex 2. A multidisciplinary treatment approach
could significantly improve the outcome of further cancer
therapies and indeed, synergistic effects of combined anticancer
therapies are described [28].
Materials and Methods
Synthesis of the ligands
Synthesis of the complexes was conducted using standard
Schlenk technique, all solvents were purified according to standard
procedures. NMR spectra were recorded on a JEOL Eclipse 400
or a Bruker Avance DRX 600 spectrometer. Structure assign-
ments were done based on 2D NMR experiments (COSY,
HMBC, HSQC). Elemental analyses were performed at the
microanalytical laboratory of the University of Constance.
The respective (20 mmol) 2,4-disubstituted phenol was sus-
pended in methanol (10 ml) and formaldehyde solution (7.5 ml,
36%) and N,N’-dimethylethylene diamine (10 mmol) were added.
The mixture was refluxed for 24 h and allowed to cool to room
temperature. Upon cooling to 6uC, the products crystallized as
colorless solids.
L
1:
1H-NMR (600 MHz, CDCl3): d=6.76 (ddd, J=11.2 Hz,
8.5 Hz, 2.6 Hz, 2H, Har), 6.50 (d, J=8.5 Hz, 2H, Har), 3.70 (s,
4H, NCH2Car), 2.69 (s, 4H, NCH2CH2N), 2.32 ppm (s, 6H,
NCH3).
13C-NMR (151 MHz, CDCl3): d=154.7 (dd,
J=239.5 Hz, 11.0 Hz, FCar), 150.7 (dd, J=246.8 Hz, 12.1 Hz,
FCar), 142.0 (dd, J=12.4 Hz, 3.3 Hz, CH2Car), 123.8 (dd,
J=8.3 Hz, 4.0 Hz, OCar), 109.9 (dd, J=23.0 Hz, 3.5 Hz, HCar),
103.9 (dd, 26.4 Hz, 22.2 Hz, HCar), 61.2 (NCH2Car), 54.1
(NCH2CH2N), 41.8 ppm (NCH3). Elemental analysis calcd (%)
for C18H20F4N2O2: C: 58.06; H: 5.41; N: 7.52, found: C: 57.98;
H: 5.40; N: 7.60. L
2:
1H-NMR (400 MHz, CDCl3): d=7.27 (d,
J=2.5 Hz, 2H, Har), 6.87 (d, J=2.5 Hz, 2H, Har), 3.70 (s, 4H,
NCH2Car), 2.72 (s, 4H, NCH2CH2N), 2.33 ppm (s, 6H, NCH3).
13C-NMR (101 MHz, CDCl3): d=152.4 (Car), 129.0 (Car), 126.8
(Car), 123.7 (Car), 123.4 (Car), 121.7 (Car), 61.0 (NCH2Car), 54.0
(NCH2CH2N), 41.8 ppm (NCH3). Elemental analysis calcd (%)
for C18H20Cl4N2O2: C: 49.34; H: 4.60; N: 6.39, found: C: 49.38;
H: 4.51; N: 6.33.
Synthesis of the complexes
The ligands (3.9 mmol) were dissolved in toluene (20 ml) and
Ti(O
iPr)4 (3.9 mmol, 420 mg, 860 ml) was added under nitrogen
atmosphere. The yellow reaction mixture was allowed to stir over
night at room temperature. The solvent was removed under
reduced pressure and the obtained yellow solid was recrystallized
to give complexes 1, 2.
1:
1H-NMR (600 MHz, CDCl3): d=6.78–6.72 (m, 2H, Har),
6.52–6.48 (m, 2H, Har), 5.09 (sept., J=6.1 Hz, 2H, TiOCH), 4.62
(d, J=13.7 Hz, 2H, NCH2Car), 3.15 (d, J=13.7 Hz, 2H,
NCH2Car), 2.97 (d, J=9.4 Hz, 2H, NCH2CH2N), 2.46 (s, 6H,
2x NCH3), 1.90 (d, J=9.4 Hz, 2H, NCH2CH2N), 1.28 (d,
J=6.2 Hz, 6H, CH(CH3)2), 1.24 ppm (d, J=6.2 Hz, 6H,
CH(CH3)2).
13C-NMR (151 MHz, CDCl3): d=153.3 (dd,
J=237.1 Hz, 11.2 Hz, FCar), 150.6 (dd, J=246.3 Hz, 12.4 Hz,
FCar), 146.5 (dd, J=12.4 Hz, 2.8 Hz, CCar), 126.0 (dd,
J=8.5 Hz, 4.1 Hz, OCar), 110.4 (dd, J=22.5 Hz, 3.3 Hz, HCar),
103.7 (dd, 26.1 Hz, 22.5 Hz, HCar4), 78.9 (TiOCH), 63.7 (dd,
J=2.8 Hz, 2.2 Hz, NCH2Car), 51.8 (NCH2CH2N), 46.9 (NCH3),
25.8 (CH(CH3)2), 25.4 ppm CH(CH3)2). Elemental analysis calcd
(%) for C24H32F4N2O4Ti: C 53.74, H 6.01, N 5.22; found: C
53.79, H 5.89, N 5.14. 2:
1H-NMR (600 MHz, CDCl3): d=7.28
(d, J=2.6 Hz, 2H, Har), 6.86 (d, J=2.6 Hz, 2H, Har), 5.21 (sept.,
J=6.1 Hz, 2H, TiOCH), 4.63 (d, J=13.6 Hz, 2H, NCH2Car),
3.14 (d, J=13.6 Hz, 2H, NCH2Car), 2.91 (d, J=9.4 Hz, 2H,
NCH2CH2N), 2.44 (s, 6H, 2x NCH3), 1.88 (d, J=9.4 Hz, 2H,
NCH2CH2N), 1.30 (d, J=6.2 Hz, 6H, CH(CH3)2), 1.23 ppm (d,
J=6.2 Hz, 6H, CH(CH3)2).
13C-NMR (151 MHz, CDCl3):
d=156.2 (Car), 129.0 (Car), 127.6 (Car), 126.1 (Car), 122.6 (Car),
121.1 (Car), 79.2 (TiOCH), 63.8 (NCH2Car), 51.7 (NCH2CH2N),
47.1 (NCH3), 26.0 (CH(CH3)2), 25.6 ppm (CH(CH3)2). Elemental
analysis calcd (%) for C24H32Cl4N2O4Ti: C 47.87, H 5.36, N 4.65;
found: C 47.97, H 5.46, N 4.68.
Cell culture
C3 tumor cells (C57BL/6 origin) derived from embryonic
mouse cells transfected with the complete HPV-16 genome [22]
were cultured in RPMI 1640 supplemented with heat-inactivated
5% (v/v) fetal calf serum (FCS, Gibco, Eggenstein, Germany),
2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 mg/ml)
Table 6. Growth of established C3 tumors in C57BL/6 mice after treatment with titanium salan complexes 1, 2.
average tumor size at
day 0 (mm
2) ± S.E.M
average tumor size at
day 29 (mm
2) ± S.E.M
number of total regressors
at day 29
complex 2
# (30 mg/kg s.a.) 2616 4 690
complex 2
* (50 mg/kg m.a.) 2611 2 632
DMSO/PBS/0.5% Tween 80 3622 6 8 624 0
Mice received tumor cells s.c. into the flank and were treated either with 50 mg/kg at multiple applications (m.a.) (day 0: 30 mg/kg and day 7: 20 mg/kg) (*) or with a
single application (s.a.) of 30 mg/kg on day 0 (
#). Data gives the mean 6 SEM at days 0 and 29 and the number of completely tumor free animals. Because of the size of
tumors in the control group the experiment was terminated at day 29. One representative of two experiments is shown.
doi:10.1371/journal.pone.0017869.t006
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atmosphere. Cells were split every three days and tested for
mycoplasma infections using a mycoplasma detection kit (Roche
Applied Science).
AlamarBlue assay with C3 cells
AlamarBlue (BioSource Europe), the dark blue colored sodium
salt of resazurin (7-Hydroxy-3H-phenoxazin-3-one-10-oxide) was
used to measure growth and viability of cells which are capable of
reducing it to the fluorescent, pink colored resorufin (7-Hydroxy-
3H-phenoxazin-3-one) [29]. Cells were seeded in 96-well plates
(1.8610
4 cells/well) and allowed to attach for 24 h. Complexes to
be tested were dissolved in a suitable amount of DMSO. Different
concentrations were prepared by serial dilution with medium to
give final concentrations with a maximum DMSO content of 1%.
The cells were then incubated for 48 h with 100 ml each of above
dilution series. AlamarBlue (10 ml) was added and the cells were
incubated for another hour. After excitation at 530 nm,
fluorescence at 590 nm was measured using a FL600 Fluorescence
Microplate Reader (Bio-TEK). Cell viability is expressed in
percent with respect to a control containing only pure medium
and 1% DMSO incubated under identical conditions. All
experiments were repeated for a minimum of three times with
each experiment done in four replicates. The resulting curves were
fitted using Sigma plot 10.0 [30].
Tumor regression studies
All animal work has been conducted according to relevant
national and international guidelines. The animal studies were
reviewed and approved by the local ethical committee (Regier-
ungspra ¨sidium Freiburg, Freiburg, Germany, approval number:
35/9185.81/G-06/48 (2008), permission given to P. O ¨ hlschla ¨ger).
C57BL/6 mice received 0.5610
6 HPV-16 E7 expressing C3 [22]
cells in 100 ml of PBS subcutaneously in the right shaved flank
(needles: 20G 1K’’ BD Microlance 3). When small tumors were
palpable in all animals (days 9–15) the first treatment (complexes 1
and 2, respectively) was applied intraperitoneally (i.p.) in 100 ml
DMSO/PBS/0.5% Tween 80 and control animals received
DMSO/PBS/0.5% Tween 80 only. The treatment was repeated
as mentioned up to five times. Tumor sizes were measured with a
caliper and were determined every 2–4 days until mice had to be
sacrificed (tumor size of 400 mm
2 or when tumors were bleeding).
Tumor sizes of the mice within a group were calculated as
arithmetic means with standard error of the means (SEMs). All
operations on live animals were performed under Isoflurane
anesthesia (CuraMed Pharma, Karlsruhe, Germany).
Statistical analysis
Differences of means between experimental and control group
were considered statistically significant when p was ,0.05 by
unpaired Students t-test.
Supporting Information
Figure S1 IC50-values of titanium salan complex 1 in
different human cancer cell lines. Dose response curves of
complex 1 in 57 different human cancer cell lines. The data show
the broad spectrum of activity of titanium salan complexes.
(TIF)
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